Great conversations today at #GU26 @ASCO (ASCO) ! @DocHariKris and I presented two posters focused on cardio-oncology, implementation, and health equity in prostate cancer. Today’s posters: •County-level educational attainment and long-term outcomes in older men with prostate cancer (SEER–Medicare 2009–2017). @virajshahr Key takeaway: Men living in lower-education counties experienced higher cardiovascular and overall mortality—highlighting community education as a potentially actionable lever for geographically targeted survivorship care. •Abstract #523882: Physician perspectives on implementing a cardiovascular risk score for prostate cancer (PRISM-guided evaluation). @ASCOPost Key takeaway: Clinicians prioritize tools that are simple, fast, and workflow-compatible—with a clear preference for lab-independent models to minimize disruption. We thank all the leaders in the field who worked with us to make this study possible. Posting video on the topic here as well @GACancerCenter @neerajaiims @zklaassen_md @mcg_urology @umangtalking @OncoAlert @oncodaily @PCFnews @IrbazRiaz @PBarataMD @AarmstrongDuke @CaPsurvivorship @PhillipKooMD @ZEROCancer @MCGCardFellows all abstracts will be available in @JCO_ASCO . Thanks to @CDMRP and @AHAScience for funding our work.

Big day in the poster hall for our group! @DocHariKris and I shared 6 posters today spanning cardio-oncology multi-omics in prostate cancer: connecting imaging, adiposity, immune remodeling, proteomics, and cardio–kidney–metabolic (CKM) risk. @TarekNahle @neerajaiims @GACancerCenter @anantm Poster lineup: •T1 MRI / radiomics: Skeletal muscle radiomic features on prostate T1-weighted MRI and association with major adverse cardiac events (MACE) @anantm •Obesity-associated epigenetic remodeling under androgen deprivation therapy (ADT) and implications for cardiometabolic risk @ImmunologyAU •CyTOF: CyTOF immune profiling: how obesity shapes biphasic immune remodeling (CD45 circulating cells) during ADT @ImmunologyAU •Proteomics: Proteomic remodeling after ADT: how age modifies innate immune/complement–ECM pathways @mayo •CardioKidneyMetabolic Syndrome: CKM syndrome stages in prostate cancer and prognostic significance for CV morbidity/mortality •MRI T2 microenvironment: Periprostatic adipose microenvironment remodeling in aggressive prostate cancer (atlas-based geometric analysis) @anantm Really appreciated all the thoughtful questions and conversations: always energizing to share the work and hear new perspectives. If you’re here, come say hi! #ProstateCancer #CardioOncology #Radiomics #Epigenetics #CyTOF #Proteomics #CKM #CancerResearch #TranslationalScience #GU26 @ASCOPost @ASCO @OelsayedMD @EmoryAIHumanity . All abstracts out in @JCO_ASCO . Thanks to @CDMRP and @AHAScience for funding our work.

New in JNCI Cancer Spectrum‼️ Socioeconomic position (SEP) meaningfully predicts cardiovascular🫀 (CV) outcomes in men with #prostate_cancer. We examined how neighborhood disadvantage shapes long-term CV and survival risks #cardiooncology #CancerResearch academic.oup.com/jncics/adva…

Presentation #5 on last day of #AHA25 by @dukemedicine #SarahMalik from @MCG_AUG - Take home - In 12,832 #ARIC participants followed for 28 years, 877 cancer survivors and 3,653 non-cancer participants developed incident CVD. Across both unmatched and propensity-matched analyses, the use of statins, anti-hypertensives, and aspirin was consistently associated with lower CVD risk in both cancer and non-cancer groups. The magnitude of benefit was comparable between groups, indicating that cancer survivors derive similar cardiovascular protection from these preventive medications as individuals without cancer. @JHUBloombergCtr @ShelbyKuttyMD @ICOSociety @oncodaily @OncoAlert

Final (#6) presentation of #AHA25 by @MCG_AUG student @sathvika_n focused on disparities in clinical trials - take home - Among 284 Southern U.S. cities, only 26% contained a Phase III lipid-lowering trial site, with a median drive time of 36 minutes to the nearest site. Each one-point increase in Area Deprivation Index (ADI) was linked to a 2.1% longer drive time (p<0.001), and moving from the 25th to 75th ADI percentile more than doubled travel burden. Minority-majority cities had 21.7% shorter drive times, largely due to trial clustering in a few large urban hubs. Overall, more socioeconomically deprived cities faced significantly longer travel distances, underscoring inequitable access to PCSK9 and lipid-lowering clinical trials. @NIMHD @trialradar

🌟 What an incredible experience presenting at #AHA25! 🎤 Honored to share our collaborative work with Memorial Sloan Kettering—advancing risk prediction in HER2 breast cancer under the mentorship of @anita_deswal 💙🫀 Grateful for the journey & teamwork #CardioOncology

🎬 Grateful for the opportunity to join Dr. Fred Kusumoto in providing #AHA25 coverage with @ACCinTouch 💙We discussed standout trials from Day 2️⃣ & previewed upcoming #HeartFailure studies, including POLY-HF & CAVIAR 🫀✨#CardioTwitter

Second presentation for the day by superstar @virajshahr - take home - Among 3,192 African American ARIC participants followed for 22.4 years, 30% developed cancer. The DARC-positive genotype was not significantly associated with overall, smoking-related, or obesity-related cancer risk (HR 0.95, 95% CI 0.83–1.09). However, DARC-null individuals with CVD showed a trend toward higher incidence of smoking-related and lung cancers, suggesting possible effect modification by cardiovascular disease. @OelsayedMD @ICOSociety

Thrilled to present our new abstract at #AHA25! 🫀 We compared traditional (BMI> 30) vs. new (BMI> 25 central adiposity) #obesity definitions in the ARIC study (25-yr follow-up).  Key Results: ✅ The new definition found a large, intermediate-risk group for CVD (aHR 1.25).

Third moderated poster by @OelsayedMD presenting moderated digital poster - take home #1 Among 14,834 ARIC participants followed for 25 years, 54% were classified as obese by the newer central adiposity definition versus 27% by the traditional BMI-based definition. The newly defined group captured individuals with BMI 25–29.9 kg/m² but high waist circumference or ratio, 7% of whom reverted to non-obese status over time. @JHUBloombergCtr

On the eve of #AHA25, I am happy to report a new paper from our lab looking to replace CHADSVASC for AF in breast cancer. Published in @Cancers_MDPI - BS2CALED - In breast cancer AF, B‑S2CALED predicts stroke/TIA better than CHA2DS2‑VASc and is externally validated. Simple 0–10 score from routine data to support anticoagulation decisions in oncology. DOI:10.3390/cancers17223600 #CardioOncology #BreastCancer #AFib #Stroke @sdent_cardioonc @nickolastab @Dr_Mike_Fradley @KoberLars

Why use this calculator? CHA2DS2‑VASc underperforms in cancer. B‑S2CALED improves discrimination (C‑index 0.64 vs 0.54 internal; 0.77 vs 0.53 external) reclassification, with 3 tiers (0 none, 1–4 low/intermediate, >4 high). #CardioOncology #BreastCancer @ICOSociety @datsunian @Breastcancerorg @DocHariKris @OelsayedMD @virajshahr @OncBrothers @OncoAlert @GACancerCenter

Find us #AHA25 (CT): Sun 11/9 11:57–12:02 @adibhave1357 HER2 ADC cardiotoxicity ( Mod poster and @JAMANetworkOpen simpub) 3:15–3:20 @OelsayedMD obesity cancer/cvd (#11 Mod post) 3:15 @VirajShahr ACKR1/DARC (post) 3:50–3:55 @TarekNahle BrCa SEER (#10 Mod poster) @ICOSociety

#AHA25 Excited to present our work from @MCG_AUG with my team: “Unequal Access: Socioeconomic Deprivation & Travel Distance to Phase III Lipid-Lowering Trials in the Southern U.S.” Join me for my moderated poster session on Mon, Nov 10 (2:06–2:11 PM CT, Population Science Zone)!

Excellent disparities work in access to modern lipid lowering trials by M1 at @MCG_AUG @sathvika_n . Inspired by an unexplained denial to an oral PCSK9 phase 3 trial, we wondered what happens when ultra modern medicine is not available to large number of patients due to biased site selection. Come see our unbiased work using @Google API to find distance to trial site. @DrMakaryFDA @US_FDA @neerajaiims @MCGCardFellows @nationallipid @AHAScience @PCSK9Forum #AHA25

Obesity is an important overlap between cancer and cardiovascular disease. We talk about it here: pubmed.ncbi.nlm.nih.gov/4084…. How does the new WHO definition: thelancet.com/commissions-do… of obesity shake up this risk factor- come and learn from @OelsayedMD at #AHA25 @AHAScience @ObesityAction @ObesityAdvocacy @LillyObesityInt @ICOSociety

We would like to inform you that your post has been published on OncoDaily.com. Thank you for sharing. oncodaily.com/voices/tarek-n…

Happening on Nov 9th: "Evaluating the Cardiotoxicity of Novel Antibody Drug Conjugates vs Standard of Care for HER2 Metastatic Breast Cancer: A Single-Arm Meta-Analysis" 📍Clinical Science Zone 2 #BreastCancer #Cardiology bit.ly/4qDJoie @WellstarHealth @AUG_University

Nov 9th, 3:15 P.M. at #AHA25: Join Dr. Omar Elsayed from @AUG_University/@WellstarHealth for the moderated poster presentation, “Comparing Traditional and Newer Definitions of Obesity in Relation to Incident Cardiovascular Disease and Cancer Risk: A Prospective Cohort Study.”

Come, check out our work funded by @AHAScience #SFRN. Learn about role of ancestral gene ACKR1 and how that changes cancer risk in those with cardiovascular disease. Previously we had shown the role of neutrophil to lymphocyte ratio. We were fortunate to collaborate with.@MeliD32 @JohnsHopkinsSPH #DrPlatz #AHA25 prior work by @OelsayedMD : ahajournals.org/doi/abs/10.1… and sciencedirect.com/science/ar… @OncoAlert @ICOSociety